HC Wainwright Has Pessimistic Outlook of DRUG Q3 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Equities researchers at HC Wainwright decreased their Q3 2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a report released on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.72). HC Wainwright has a "Buy" rating and a $85.00 price target on the stock. The consensus estimate for Bright Minds Biosciences' current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Bright Minds Biosciences' Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($2.30) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.79) EPS, FY2026 earnings at ($5.63) EPS, FY2027 earnings at ($5.72) EPS, FY2028 earnings at ($5.80) EPS and FY2029 earnings at ($1.70) EPS.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.24.

A number of other research analysts also recently issued reports on DRUG. Robert W. Baird assumed coverage on Bright Minds Biosciences in a report on Monday, November 25th. They set an "outperform" rating and a $75.00 price objective for the company. Baird R W upgraded shares of Bright Minds Biosciences to a "strong-buy" rating in a report on Monday, November 25th. Piper Sandler began coverage on shares of Bright Minds Biosciences in a report on Thursday, January 23rd. They set an "overweight" rating and a $93.00 target price for the company. Finally, Cantor Fitzgerald started coverage on shares of Bright Minds Biosciences in a research report on Friday, January 10th. They issued an "overweight" rating for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $84.33.

Bright Minds Biosciences Price Performance

Shares of DRUG traded down $1.91 during midday trading on Friday, hitting $34.03. The stock had a trading volume of 99,441 shares, compared to its average volume of 83,090. The firm has a market cap of $239.57 million, a price-to-earnings ratio of -200.16 and a beta of -6.71. The company has a 50 day simple moving average of $37.92 and a two-hundred day simple moving average of $27.08. Bright Minds Biosciences has a twelve month low of $0.93 and a twelve month high of $79.02.

Institutional Investors Weigh In On Bright Minds Biosciences

Several large investors have recently made changes to their positions in DRUG. Atika Capital Management LLC acquired a new stake in Bright Minds Biosciences in the fourth quarter valued at $540,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in Bright Minds Biosciences in the 4th quarter valued at about $2,185,000. Walleye Capital LLC acquired a new stake in Bright Minds Biosciences in the 4th quarter valued at about $3,717,000. Vivo Capital LLC bought a new position in Bright Minds Biosciences during the fourth quarter worth about $9,062,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Bright Minds Biosciences during the fourth quarter worth approximately $4,773,000. Institutional investors and hedge funds own 40.52% of the company's stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.